MDRX
Veradigm Inc.·Healthcare
4.49
6.651%(+0.28)
Close PriceLast Updated: — ET
52W L: $3.0052W H: $6.00
MDRX NEWS
businesswire.com
Apr 6
Veradigm Appoints Christian Greyenbuhl as Chief Financial Officer
CHICAGO--(BUSINESS WIRE)--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced the appointment of Christian Greyenbuhl as Chief Financial Officer of the Company, effective on the later of May 11, 2026 and the first business day after Veradigm files its Annual Report on Form 10-K for its 2023 and 2024 fiscal years, or as otherwise agreed. Mr. Greyenbuhl is a seasoned operator and finance executive with more than 25 years o.
seekingalpha.com
Feb 18
Veradigm Inc. (MDRX) Discusses Strategic Reset, Product Portfolio Decisions and Growth Initiatives Transcript
Veradigm Inc. (MDRX) Discusses Strategic Reset, Product Portfolio Decisions and Growth Initiatives Transcript
businesswire.com
Feb 17
Veradigm Provides Business and Strategy Update
CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, is providing estimated financial performance for the fiscal year 2025 and key areas of strategic focus for 2026. “On my first investor call in October, I committed to advancing three strategic objectives in my first 100 days: reset our business strategy, recover our market leadership with independent physician practices and reignite profitable growth,” said.
businesswire.com
Feb 13
Veradigm Brings Patient Voice to Healthcare Research with New Real-World Data Survey Solution
CHICAGO--(BUSINESS WIRE)--Veradigm (OTCMKTS:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced a new patient‑reported outcomes (PRO) survey capability that brings the patient voice directly into real‑world evidence generation. The new solution gives life sciences organizations timely, privacy‑preserving insights directly from patients, adding essential context to clinical and observational research. Built on Veradigm's FollowMyHealth pat.
businesswire.com
Feb 10
Veradigm to Release Business Update February 17th and Host Investor Call February 18th
CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management plans to provide a business update after the close of regular stock market hours on February 17, 2026. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on February 18, 2026. Update Call Details Veradigm plans to issue a press release after the c.
businesswire.com
Feb 2
Veradigm Extends Stockholder Rights Plan
CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced that its Board of Directors (the “Board”) has approved an amendment to extend the Company's existing Stockholder Rights Plan to December 31, 2026 (the “Rights Plan”). The Board's decision to extend the Rights Plan is based on its determination that many of the underlying risks and conditions that existed upon the initial adoption of the Right.
